Literature DB >> 17805556

Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.

Aya Iriyama1, Ryo Obata, Yuji Inoue, Hidenori Takahashi, Yasuhiro Tamaki, Yasuo Yanagi.   

Abstract

PURPOSE: To evaluate the effect of posterior juxtascleral triamcinolone acetonide (TA) injection combined with photodynamic therapy with verteporfin (PDT) for treating exudative age-related macular degeneration (AMD), the best-corrected visual acuity (BCVA), the retreatment rates and the rate of choroidal hypoperfusion were investigated.
METHODS: A total of 67 eyes with subfoveal choroidal neovascularization (CNV) due to AMD were included. Forty-four eyes underwent PDT alone (PDT-alone group), and 23 eyes underwent PDT with the posterior juxtascleral injection of TA (PDT+TA group). Every 3 months after the PDT, the eyes were evaluated with regard to BCVA and requirement for retreatment by fluorescein angiography (FA) with the aid of optical coherence tomography (OCT). Choroiocapillaris hypoperfusion was assessed by indocyanine green angiography (ICGA) at 3 and 12 months. All patients completed a 1-year follow-up.
RESULTS: At the baseline, there was no difference in lesion type, size or visual acuity between the two groups. At 1 year, the change in BCVA was -0.0811 logarithm of the minimum angle of resolution (LogMAR) in the PDT-alone group, compared with -0.0432 logMAR in the PDT+TA group. There was no significant difference in the change in BCVA between the two groups (P = 0.6910). The PDT+TA group required a lower mean number of treatments (1.64 compared with 2.34 [P = 0.0223]) and showed a higher rate of choriocapillaris occlusion at 3 months, but no significant difference at 1 year (P = 0.9243)
CONCLUSIONS: Fewer retreatments were required in the TA+PDT group. There was no significant difference in the change in BCVA between the two groups. Adjacent TA may promote short-term choriocapillaris hypoperfusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805556     DOI: 10.1007/s00417-007-0667-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Theoretical investigation of the role of choriocapillaris blood flow in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.

Authors:  R W Flower; C von Kerczek; L Zhu; A Ernest; C Eggleton; L D Topoleski
Journal:  Am J Ophthalmol       Date:  2001-07       Impact factor: 5.258

3.  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Peter Stalmans; Claus Eckardt; Matthias Lüke; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

5.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

Authors:  R Obata; A Iriyama; Y Inoue; H Takahashi; Y Tamaki; Y Yanagi
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

6.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

7.  Influence of treatment parameters on selectivity of verteporfin therapy.

Authors:  Stephan Michels; Fabian Hansmann; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

8.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2005-02       Impact factor: 12.079

9.  Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

10.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors: 
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258

View more
  7 in total

1.  Nerve fiber layer thickness in exudative age-related macular degeneration in Japanese patients.

Authors:  Kentaro Yuda; Yuji Inoue; Atsuo Tomidokoro; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-31       Impact factor: 3.117

2.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

3.  Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Authors:  Koko Saito; Teiko Yamamoto; Daijiro Tsuchiya; Ryo Kawasaki; Shion Haneda; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

4.  Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system.

Authors:  Wei Zhao; Yu-Sheng Wang; Yan-Nian Hui; Jie Zhu; Peng Zhang; Xia Li; Guo-Rui Dou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-04       Impact factor: 3.117

5.  One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration.

Authors:  Tomoko Nakamura; Akio Miyakoshi; Kazuya Fujita; Tatsuya Yunoki; Keiichi Mitarai; Shuichiro Yanagisawa; Chiharu Fuchizawa; Atsushi Hayashi
Journal:  J Ophthalmol       Date:  2011-12-07       Impact factor: 1.909

6.  Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial.

Authors:  Niloofar Piri; Hamid Ahmadieh; Ramin Taei; Masoud Soheilian; Reza Karkhaneh; Alireza Lashay; Faegheh Golbafian; Mehdi Yaseri; Mohammad Riazi-Esfahani
Journal:  J Ophthalmic Vis Res       Date:  2014 Oct-Dec

Review 7.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.